The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the ...

Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Patients with locally advanced ...

Improvements in some domains of cognitive function seen for patients with cancer receiving chemotherapy reporting cognitive problems.

Nubeqa plus ADT improved HRQoL and delayed pain progression in mHSPC patients, outperforming placebo plus ADT. The FDA approved Nubeqa for mHSPC based on ARANOTE trial data, highlighting its clinical ...

Suggested Citation: "9 Cancer-Related Impairments Leading to Functional Limitations." National Academies of Sciences, Engineering, and Medicine. 2021. Diagnosing and Treating Adult Cancers and ...

A global phase 3 trial enrolled mHSPC with ≥90% PTEN loss by IHC and randomized 1,012 patients to intermittent capivasertib plus abiraterone/prednisone versus ...

Exagamglogene autotemcel (exa-cel) significantly improved HRQOL in severe SCD patients, eliminating severe VOCs and hospitalizations in most cases. The CLIMB SCD-121 trial showed sustained ...

Please provide your email address to receive an email when new articles are posted on . Real and sham acupuncture improved perceived cognitive impairment from breast cancer treatment compared with ...